StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.1
  1. Startseite
  2. /Verbindung

3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid

HCID 5538
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
78996-15-3
Standard-SMILES
CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O
InChIKey
SHGAZHPCJJPHSC-UHFFFAOYSA-N
Summenformel
C20H28O2
Durchschnittliche Molmasse
300,4 g/mol
Monoisotopische Masse
300,20893013

Überblick

Retinoic acid is a retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified). It has a role as a human metabolite. It is a retinoid and an alpha,beta-unsaturated monocarboxylic acid. It is a conjugate acid of a retinoate.

Namen und Bezeichner

Bevorzugter Name
3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
IUPAC
3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
Englischer Name
SHGAZHPCJJPHSC-GOWYKSNKSA-N
Summenformel
C20H28O2
Molmasse
300.44

Namen und Synonyme

3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acidRefChem:106615311-cis Retinoic Acid3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acidTretinoina (INN-Spanish)Tretinoina [INN-Spanish]Isotretinoin EP Impurity CAvita (0.025% gel)retinylpalmitats1653LGD 100057Spectrum_001676
Weitere Namen anzeigen
D5-IsotretinoinRetinoic acid-dRetinoic Acid-d5SHGAZHPCJJPHSC-GOWYKSNKSA-NRetinoic-4,4,18,18,18-d5 acidIsotretinoin D5Q: What is Isotretinoin D5 Q: What is the CAS Number of Isotretinoin D5 Q: What is the storage condition of Isotretinoin D5 Q: What are the applications of Isotretinoin D5
SpecPlus_000696Prestwick0_000256Prestwick0_000257Prestwick1_000256Prestwick1_000257Spectrum2_001983Spectrum3_001793Spectrum4_000901

Eigenschaften

Berechnete Struktureigenschaften

XLogP
6,3
Polarare Oberfläche (TPSA)
37,3 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
5
Schwere Atome
22
Formalladung
0
Komplexität
567

Experimentelle und physikochemische Eigenschaften

LogP6.3

Physikochemische Eigenschaften

storage temp.
-80 °C · Store at -80°C
Löslichkeit
Methanol: Soluble
Aggregatzustand
A solid
Farbe
White to off-white

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

Exposure Routes1-31% (topical)
Toxicity Summary · 1 Eintrag

Tretinoin binds to alpha, beta, and gamma retinoic acid receptors (RARs). RAR-alpha and RAR-beta have been associated with the development of acute promyelocytic leukemia and squamous cell cancers, respectively. RAR-gamma is associated with retinoid effects on mucocutaneous tissues and bone. Although the exact mechanism of action of tretinoin is unknown, current evidence suggests that the effectiveness of tretinoin in acne is due primarily to its ability to modify abnormal follicular keratinization. Comedones form in follicles with an excess of keratinized epithelial cells. Tretinoin promotes detachment of cornified cells and the enhanced shedding of corneocytes from the follicle. By increasing the mitotic activity of follicular epithelia, tretinoin also increases the turnover rate of thin, loosely-adherent corneocytes. Through these actions, the comedo contents are extruded and the formation of the microcomedo, the precursor lesion of acne vulgaris, is reduced. Tretinoin is not a cytolytic agent but instead induces cytodifferentiation and decreased proliferation of APL cells in culture and in vivo. When Tretinoin is given systemically to APL patients, tretinoin treatment produces an initial maturation of the primitive promyelocytes derived from the leukemic clone, followed by a repopulation of the bone marrow and peripheral blood by normal, polyclonal hematopoietic cells in patients achieving complete remission (CR). The exact mechanism of action of tretinoin in APL is unknown.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Chemie und Industrie

Pharmakologische Informationen

Metabolism/MetabolitesHepatic Half Life: 0.5-2 hours

Verwendung und Herstellung

Uses · 1 Eintrag

For the the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant); For the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (Darier's disease), and basal cell carcinomas.); For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage.

Anwendungen · 2 Einträge

Beschreibung13-cis Retinoic acid-d5 is intended for use as an internal standard for the quantification of 13-cis retinoic acid by GC- or LC-MS. 13-cis Retinoic acid is a naturally occurring retinoid that inhibits retinol oxidation and dehydrogenation of 17β-hydroxy steroids.

VerwendenAn endogenous retinoic acid isomer, which is capable of binding to both retinoic acid receptors (RAR) and retinoid X receptors (RXR). A biologically active ligand for members of the RAR and RXR subfamilies, implying that it may play a critical role in regulating retinoid-responsive pathways.

Zugehörige Reaktionen

8
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 140142
HRID 140142als ProduktTraining data from https://doi.org/10.1039/C8SC04228D (9/10)
Reaktionsgleichung von HRID 171983
HRID 171983als EduktTraining data from https://doi.org/10.1039/C8SC04228D (9/10)
Reaktionsgleichung von HRID 179424
HRID 179424als EduktTraining data from https://doi.org/10.1039/C8SC04228D (6/10)
Reaktionsgleichung von HRID 184668
HRID 184668als Produktals EduktTraining data from https://doi.org/10.1039/C8SC04228D (6/10)
Reaktionsgleichung von HRID 1142109
HRID 1142109als ProduktTraining data from https://doi.org/10.1039/C8SC04228D (7/10)
Reaktionsgleichung von HRID 1149157
HRID 1149157als ProduktTraining data from https://doi.org/10.1039/C8SC04228D (7/10)
Reaktionsgleichung von HRID 1228653
HRID 1228653als EduktTraining data from https://doi.org/10.1039/C8SC04228D (5/10)
Reaktionsgleichung von HRID 1238402
HRID 1238402als Produktals EduktTraining data from https://doi.org/10.1039/C8SC04228D (5/10)

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
78996-15-3
PubChem CID
5538
ChEMBL
CHEMBL1235644
ChEBI
CHEBI:26536